Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized Double-blind Phase 3 Study (KEYNOTE 716)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
